BioWorld

BioWorld Today provides valuable insights into groundbreaking drug development that fuels the healthcare industry and helps combat diseases. With a team of writers and editors located worldwide, BioWorld Today covers the latest news and offers essential viewpoints on numerous medicines in the pipeline, the companies developing these treatments, the business deals shaping the industry, and the regulatory challenges that both hinder and protect the process.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#296876

China

#35027

Articles

Abvance Therapeutics secures seed funding to limit glucose lows

1 day ago | bioworld.com | Brian Orelli

Home » Abvance Therapeutics secures seed funding to limit glucose lows BioWorld briefs for June 26, 2025. BioWorld MedTech briefs for June 25, 2025. Although the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) was scheduled to vote June 25 on recommendations for maternal and pediatric... BioWorld Asia briefs for June 24, 2025 Kymera Therapeutics Inc. found itself juggling partnerships by bringing one on board while going to the development bench in another.
Abion strikes $1.3B antibody drug deal with unidentified partner

2 days ago | bioworld.com | Marian Chu

Home » Abion strikes $1.3B antibody drug deal with unidentified partner BioWorld briefs for June 25, 2025. BioWorld MedTech briefs for June 24, 2025. Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
Two new options presented at ADA for early diagnosis of T1D

3 days ago | bioworld.com | Annette Boyle

ADA 2025Two new options presented at ADA for early diagnosis of T1DClassically, the diagnosis of type 1 diabetes comes after a patient presents with unexplained weight loss, extreme thirst and frequent urination and a lab test reveals off-the-charts blood glucose levels.
AID system improves glycemic control in pregnancy

3 days ago | bioworld.com | Annette Boyle

ADA 2025AID system improves glycemic control in pregnancyPregnant women with type 1 diabetes who used a hybrid closed loop automated insulin delivery system averaged more than three additional hours per day in their recommended glucose range than those who managed their diabetes with insulin injections or non-automated pump systems, a study presented at the 85th Scientific Sessions of the American Association in Chicago demonstrated.
Moderna expands mRNA tech to latent viruses, cancer, rare disease

3 days ago | bioworld.com | Marian Chu

Home » Moderna expands mRNA tech to latent viruses, cancer, rare disease BioWorld briefs for June 23, 2025. BioWorld MedTech briefs for June 23, 2025. BioWorld Asia briefs for June 24, 2025 Harbour Biomed is out-licensing its B-cell maturation antigen and CD3 bispecific T-cell engager HBM-7020 for autoimmune diseases to Otsuka Pharmaceutical Co. Ltd.... In a bid to boost its multiomics holdings, Illumina Inc. reported an agreement to buy proteomics technology company Somalogic Inc.
Transthera raises $25M with Hong Kong IPO; stock up 78% on debut

3 days ago | bioworld.com | Marian Chu

Illumina buying Somalogic for up to $425M to boost multiomics assetsIn a bid to boost its multiomics holdings, Illumina Inc. reported an agreement to buy proteomics technology company Somalogic Inc. from Standard Biotools Inc. for...
\Jyong’s $20M US IPO to help refile NDA of urological botanic drug

3 days ago | bioworld.com | Marian Chu

Jyong Biotech Ltd. raised $20 million from its Nasdaq debut June 17 to advance a pipeline of botanical drugs targeting male urinary disorders. The New Taipei City, Taiwan-headquartered company’s shares began trading under the ticker MENS, and closed at $10.11 apiece at the bell, up 34.80% from its listing price of $7.50 per share. Shares had kicked up to $15 at opening, reaching double its offering price.
Drug Farm harvests new immunomodulators with AI-gene editing tech

3 days ago | bioworld.com | Marian Chu

Shanghai Yao Yuan Biotechnology Ltd., also known as Drug Farm, is advancing a portfolio of immune-modulating therapies for various indications including hepatitis B virus (HBV), hepatocellular cancer (HCC) and a relatively new rare genetic disease called ROSAH, an acronym for retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and headache.
Hearts break as Carmat faces insolvency

4 days ago | bioworld.com | Annette Boyle

Home » Hearts break as Carmat faces insolvency BioWorld briefs for June 23, 2025. BioWorld MedTech briefs for June 20, 2025. To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small... BioWorld Asia briefs for June 17, 2025 With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
Fractyl pursues dual track to cure T2 diabetes

4 days ago | bioworld.com | Annette Boyle

Fractyl pursues dual track to cure T2 diabetesAt the American Diabetes Association 85th Scientific Sessions in Chicago June 20-23, Fractyl Health Inc. presented results from two studies evaluating very different approaches to treating – and possibly curing – type 2 diabetes. BioWorld MedTech Clinical American Diabetes Association Diabetes Obesity